Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1307-1313

  Fernandez, C A ^a   Stewart, E ^a   Panetta, J C ^a   Wilkinson, M R ^a   Morrison, A R ^a   Finkelman, F D ^b,c,d   Sandlund, J T ^a   Pui, C H ^a   Jeha, S ^a   Relling, M V ^a   Campbell, P K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Anti asparaginase antibody; Asparaginase; Asparaginase activity; Hypersensitivity; Pediatric

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; CASE REPORT; CHILD; CHILDHOOD LEUKEMIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; PANCREATITIS; PRIORITY JOURNAL; SCHOOL CHILD; SUPERIOR CAVA VEIN SYNDROME; SYMPTOMATOLOGY; VEIN THROMBOSIS;

ADOLESCENT; ASPARAGINASE; CHILD; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; PECTOBACTERIUM CHRYSANTHEMI; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84903816170     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2464-2     Document Type: Article

References (20)

1. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11:1780-1786 (Pubitemid 23277332)
2. Raetz EA, Salzer WL (2010) Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 32(7):554-563. doi:10.1097/MPH.0b013e3181e6f003
3. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41:4554-4558 (Pubitemid 12201374)
4. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R (2007) FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12(8):991-998. doi:10.1634/theoncologist.12-8-991 (Pubitemid 47359142)
5. Muller HJ, Boos J (1998) Use of L-asparaginase in childhood ALL. Crit Rev Oncol/Hematol 28(2):97-113 (Pubitemid 28390409)
6. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH, Relling MV (1998) Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12(10):1527-1533 (Pubitemid 28470435)
7. Asselin BL (1999) The three asparaginases-comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 457:621-629
8. Avramis VI, Avramis EV, Hunter W, Long MC (2009) Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res 29(1):299-302
9. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, Hak LJ (2003) Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17(8):1583-1588 (Pubitemid 36992159)
10. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97(5):1211-1218 (Pubitemid 32183741)
11. Pui CHCD, Sandlund JT, Bhojwani D, Evans WE, Relling MV, Jeha S (2011) Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. Ann Hematol 90(Suppl 1):S61-S63
12. Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, Pui CH, Relling MV (2009) Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 86(6):651-658. doi:10.1038/clpt.2009.162
13. Payne V, Kam PC (2004) Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 59(7):695-703. doi:10.1111/j.1365-2044.2004. 03757.x (Pubitemid 38997011)
14. Richter AW, Akerblom E (1984) Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 74(1):36-39 (Pubitemid 14136479)
15. Beal S, Sheiner L, Boeckmann A (1989-2011) NONMEM user's guides. Icon Development Solutions, Ellicott City, MD
16. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's cancer group study. Blood 99(6):1986-1994 (Pubitemid 34525479)
17. Avramis VI, Panosyan EH (2005) Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44(4):367-393 (Pubitemid 40663683)
18. Ho DHW, Yap HY, Brown N, Benjamin RS, Friereich EJ, Blumenschein GR, Bodey GP (1981) Clinical pharmacology of intramuscularly administered L-asparaginase. J Cancer Res Clin Oncol 21:72-78
19. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia Consortium Protocol 85-01. J Clin Oncol 12(4):740-747
20. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV (2012) Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. doi:10.1038/leu.2012.102